Top

Published in:

Open Access 01-12-2021 | Hypertension | Research

Serum complement proteomics reveal biomarkers for hypertension disorder of pregnancy and the potential role of Clusterin

Authors: Shanshui Zeng, Mengru Han, Min Jiang, Fei Liu, Yanwei Hu, Yan Long, Chunyan Zhu, Fangling Zeng, Qiangsheng Gan, Weitao Ye, Wenjin Fu, Hongling Yang

Published in: Reproductive Biology and Endocrinology | Issue 1/2021

Abstract

Introduction

Hypertension disorder of pregnancy (HDP) is one of the leading causes of maternal and foetal illness. The aim of the current study was to identify and verify novel serum markers for HDP.

Methods

A label-free LC-MS/MS method was used to establish the serum proteomic profiles of 12 pre-HDP (before clinical diagnosis of HDP) pregnancies and verify prioritized candidates in the verification set of 48 pre-HDP pregnancies. These biomarkers were revalidated by ELISA in an independent cohort of 88 pre-HDP pregnancies. Subsequently, the candidate biomarkers were histologically analysed by immunohistochemistry, and function was evaluated in TEV-1 cells.

Results

We identified 33 proteins with significantly increased abundance and 14 with decreased abundance (peptide FDR ≤ 1%, P < 0.05). Complement was one of the top enriched components in the pre-HDP group compared with the control group. Three complement factors (CLU, CFHR5, and CRP) were significantly increased in the three sets, of which CLU was a critical factor for the development of HDP (OR = 1.22, P < 0.001). When these three factors and body weight were combined, the AUC was 0.74, with a sensitivity of 0.67 and specificity of 0.68 for HDP prediction compared with normal pregnancy. In addition, inflammation-induced CLU could inhibit the invasion of TEV-1 cells.

Conclusions

Complement proteins may play an essential role in the occurrence of HDP by acting on trophoblast cells. CLU may be a high-risk factor for HDP, and the models combining candidates show reasonable screening efficiency of HDP in the first half of pregnancy.

Available only for authorised users

Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis. Hypertens Res. 2017;40(3):213–20. https://doi.org/10.1038/hr.2016.126.CrossRefPubMed

Behrens I, Basit S, Melbye M, Lykke JA, Wohlfahrt J, Bundgaard H, et al. Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. BMJ. 2017;358:j3078.CrossRef

Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. Lancet. 2016;387(10022):999–1011. https://doi.org/10.1016/S0140-6736(15)00070-7.CrossRefPubMed

ACOG Practice Bulletin No. 202: gestational hypertension and preeclampsia. Obstet Gynecol. 2019;133:e1–25.

US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, et al. Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. JAMA. 2017;317:1661–7.CrossRef

Nobakht M, Gh BF. Application of metabolomics to preeclampsia diagnosis. Syst Biol Reprod Med. 2018;64:324–39. https://doi.org/10.1080/19396368.2018.1482968.CrossRef

Borzychowski AM, Sargent IL, Redman CWG. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med. 2006;11:309–16. https://doi.org/10.1016/j.siny.2006.04.001.CrossRefPubMed

Yang H, Tang W, Zhu C, Guo C. Platelets, inflammation, and prediction of the hypertension disorders of pregnancy. J Matern Fetal Neonatal Med. 2012;25:99–103. https://doi.org/10.3109/14767058.2011.560985.CrossRefPubMed

Yang H, Wang Q, Tang W, Zhu C, Xiao Y, Wang J. The predictive value of leukocyte parameters for hypertensive disorders of pregnancy in South China. Hypertension in Pregnancy. 2012;31:11–21. https://doi.org/10.3109/10641955.2010.507836.CrossRefPubMed

10.

Ma Y, Kong L-R, Ge Q, Lu Y-Y, Hong M-N, Zhang Y, et al. Complement 5a-mediated trophoblasts dysfunction is involved in the development of pre-eclampsia. J Cell Mol Med. 2018;22:1034–46. https://doi.org/10.1111/jcmm.13466.

11.

Teirilä L, Heikkinen-Eloranta J, Kotimaa J, Meri S, Lokki AI. Regulation of the complement system and immunological tolerance in pregnancy. Semin Immunol. 2019;45:101337. https://doi.org/10.1016/j.smim.2019.101337.CrossRefPubMed

12.

Geyer PE, Holdt LM, Teupser D, Mann M. Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol. 2017;13:942. https://doi.org/10.15252/msb.20156297.CrossRefPubMedPubMedCentral

13.

Murphy MS-Q, Bytautiene E, Saade G, Smith GN. Alterations to the maternal circulating proteome after preeclampsia. Am J Obstetr Gynecol. 2015;213:853.e1–9.CrossRef

14.

Blankley RT, Fisher C, Westwood M, North R, Baker PN, Walker MJ, et al. A label-free selected reaction monitoring workflow identifies a subset of pregnancy specific glycoproteins as potential predictive markers of early-onset pre-eclampsia. Mol Cell Proteomics. 2013;12:3148–59. https://doi.org/10.1074/mcp.M112.026872.

15.

Muhammad LA, Saad F. The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target. Expert Rev Anticancer Ther. 2015;15:1049–61. https://doi.org/10.1586/14737140.2015.1064769.CrossRefPubMed

16.

Pucci S, Greggi C, Polidoro C, Piro MC, Celi M, Feola M, et al. Clusterin silencing restores myoblasts viability and down modulates the inflammatory process in osteoporotic disease. J Transl Med. 2019;17:118. https://doi.org/10.1186/s12967-019-1868-5.

17.

Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523. https://doi.org/10.1038/s41467-019-09234-6.

18.

Jiang M, Lash GE, Zeng S, Liu F, Han M, Long Y, et al. Differential expression of serum proteins before 20 weeks gestation in women with hypertensive disorders of pregnancy: a potential role for SH3BGRL3. Placenta. 2021;104:20–30. https://doi.org/10.1016/j.placenta.2020.10.031.

19.

Lynch AM, Murphy JR, Byers T, Gibbs RS, Neville MC, Giclas PC, et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstetr Gynecol. 2008;198:385.e1–9.CrossRef

20.

Lynch A, Murphy J, Gibbs R, Levine R, Giclas P, Salmon J, et al. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia: complement, angiogenesis, pre-eclampsia and obesity. BJOG Int J Obstet Gynaecol. 2010;117:456–62. https://doi.org/10.1111/j.1471-0528.2009.02473.x.

21.

Kim SM, Cho B-K, Kang MJ, Norwitz ER, Lee SM, Lee J, et al. Expression changes of proteins associated with the development of preeclampsia in maternal plasma: a case-control study. Proteomics. 2016;16:1581–9. https://doi.org/10.1002/pmic.201500381.

22.

Kolla V, Jenö P, Moes S, Lapaire O, Hoesli I, Hahn S. Quantitative proteomic (iTRAQ) analysis of 1st trimester maternal plasma samples in pregnancies at risk for preeclampsia. J Biomed Biotechnol. 2012;2012:305964.CrossRef

23.

Alrahmani L, Willrich MAV. The complement alternative pathway and preeclampsia. Curr Hypertens Rep. 2018;20:40. https://doi.org/10.1007/s11906-018-0836-4.CrossRefPubMed

24.

Fakhouri F, Jablonski M, Lepercq J, Blouin J, Benachi A, Hourmant M, et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood. 2008;112:4542–5. https://doi.org/10.1182/blood-2008-03-144691.

25.

Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, et al. Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort. M. Fisk N. PLoS Med. 2011;8:e1001013.CrossRef

26.

Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta. 2013;34:201–3. https://doi.org/10.1016/j.placenta.2012.11.014.CrossRefPubMed

27.

Csincsi ÁI, Kopp A, Zöldi M, Bánlaki Z, Uzonyi B, Hebecker M, et al. Factor H-related protein 5 interacts with pentraxin 3 and the extracellular matrix and modulates complement activation. J Immunol. 2015;194:4963–73. https://doi.org/10.4049/jimmunol.1403121.

28.

Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13:300–17. https://doi.org/10.2215/CJN.00620117.CrossRefPubMed

29.

Chen Q, Manzke M, Hartmann A, Büttner M, Amann K, Pauly D, et al. Complement factor H-related 5-hybrid proteins anchor Properdin and activate complement at self-surfaces. J Am Soc Nephrol. 2016;27:1413–25. https://doi.org/10.1681/ASN.2015020212.

30.

Wilson MR, Zoubeidi A. Clusterin as a therapeutic target. Expert Opin Ther Targets. 2017;21:201–13. https://doi.org/10.1080/14728222.2017.1267142.CrossRefPubMed

31.

Mohanty G, Jena SR, Nayak J, Kar S, Samanta L. Quantitative proteomics decodes clusterin as a critical regulator of paternal factors responsible for impaired compensatory metabolic reprogramming in recurrent pregnancy loss. Andrologia. 2020;52:e13498.CrossRef

32.

Oztas E, Ozler S, Ersoy AO, Iskender CT, Sucak A, Ergin M, et al. Increased levels of serum clusterin is associated with intrauterine growth restriction and adverse pregnancy outcomes in preeclampsia. J Perinat Med. 2016;44. https://doi.org/10.1515/jpm-2015-0120.

33.

Blumenstein M, McCowan LME, Wu S, Cooper GJS, North RA, SCOPE consortium. Plasma clusterin increased prior to small for gestational age (SGA) associated with preeclampsia and decreased prior to SGA in normotensive pregnancies. Reprod Sci. 2012;19:650–7.CrossRef

34.

Huppertz B. Traditional and new routes of Trophoblast invasion and their implications for pregnancy diseases. Int J Mol Sci. 2019;21. https://doi.org/10.3390/ijms21010289.

35.

Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. Lancet. 2016;387(10022):999–1011. https://doi.org/10.1016/S0140-6736(15)00070-7.CrossRefPubMed

36.

Jin R, Chen X, Han D, Luo X, Li H. Clusterin modulates transdifferentiation of non-small-cell lung cancer. BMC Cancer. 2017;17:661. https://doi.org/10.1186/s12885-017-3649-y.CrossRefPubMedPubMedCentral

37.

Jeong S, Ledee DR, Gordon GM, Itakura T, Patel N, Martin A, et al. Interaction of clusterin and matrix metalloproteinase-9 and its implication for epithelial homeostasis and inflammation. Am J Pathol. 2012;180:2028–39. https://doi.org/10.1016/j.ajpath.2012.01.025.

38.

Geldenhuys J, Rossouw TM, Lombaard HA, Ehlers MM, Kock MM. Disruption in the regulation of immune responses in the placental subtype of preeclampsia. Front Immunol. 2018;9:1659. https://doi.org/10.3389/fimmu.2018.01659.CrossRefPubMedPubMedCentral

39.

Friedman SA, de Groot CJ, Taylor RN, Golditch BD, Roberts JM. Plasma cellular fibronectin as a measure of endothelial involvement in preeclampsia and intrauterine growth retardation. Am J Obstet Gynecol. 1994;170:838–41. https://doi.org/10.1016/S0002-9378(94)70295-0.CrossRefPubMed

40.

Wright SD, Craigmyle LS, Silverstein SC. Fibronectin and serum amyloid P component stimulate C3b- and C3bi-mediated phagocytosis in cultured human monocytes. J Exp Med. 1983;158:1338–43. https://doi.org/10.1084/jem.158.4.1338.CrossRefPubMed

41.

Gelber SE, Brent E, Redecha P, Perino G, Tomlinson S, Davisson RL, et al. Prevention of defective placentation and pregnancy loss by blocking innate immune pathways in a syngeneic model of placental insufficiency. J Immunol. 2015;195:1129–38. https://doi.org/10.4049/jimmunol.1402220.

42.

Moussavi-Harami SF, Annis DS, Ma W, Berry SM, Coughlin EE, Strotman LN, et al. Characterization of molecules binding to the 70K N-terminal region of Fibronectin by IFAST purification coupled with mass spectrometry. J Proteome Res. 2013;12:3393–404. https://doi.org/10.1021/pr400225p.

Title: Serum complement proteomics reveal biomarkers for hypertension disorder of pregnancy and the potential role of Clusterin
Authors: Shanshui Zeng
Mengru Han
Min Jiang
Fei Liu
Yanwei Hu
Yan Long
Chunyan Zhu
Fangling Zeng
Qiangsheng Gan
Weitao Ye
Wenjin Fu
Hongling Yang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Hypertension
Pre-Eclampsia
Hypertensive Disorder of Pregnancy
Hypertension
Biomarkers
Published in: Reproductive Biology and Endocrinology / Issue 1/2021
Electronic ISSN: 1477-7827
DOI: https://doi.org/10.1186/s12958-021-00742-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum complement proteomics reveal biomarkers for hypertension disorder of pregnancy and the potential role of Clusterin

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Effect of resveratrol on mouse ovarian vitrification and transplantation

Aquaporin 3 promotes human extravillous trophoblast migration and invasion

Association between abnormal body mass index and pregnancy outcomes in patients following frozen embryo transfer: a systematic review and meta-analysis

BPA and BPS affect the expression of anti-Mullerian hormone (AMH) and its receptor during bovine oocyte maturation and early embryo development

Differences in ICSI utilization rates among states with insurance mandates for ART coverage

Association of ABO blood groups with ovarian reserve, and outcomes after assisted reproductive technology: systematic review and meta-analyses